Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Seattle Genetics

Seattle Genetics?uq=kzBhZRuG
1998 FOUNDED
PUBLIC STATUS
1K-5K EMPLOYEES
SGEN STOCK SYMBOL
3 INVESTMENTS
$73.33 SHARE PRICE (As of Friday Closing)
Description

Developer of antibody-based therapies designed to offer treatment of cancer. The company's antibody-based therapies offers advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells, enabling doctors to improve patient outcomes.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 21823 - 30th Drive South East
  • Bothell, WA 98021
  • United States

+1 (425) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Seattle Genetics’s full profile, request a free trial.

Seattle Genetics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$45.92 - $73.33 $11.4B $72.06 -$0.30 851K 159M

Seattle Genetics Financials Summary

In Thousands,
USD
TTM
30-Jun-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 10,056,543 7,286,995 6,880,747 5,618,918
Revenue 575,659 482,250 418,147 336,802
EBITDA (50,092) (134,618) (122,077) (105,981)
Net Income (44,622) (125,530) (140,111) (120,486)
Total Assets 1,580,917 877,949 838,396 895,095
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Seattle Genetics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Seattle Genetics‘s full profile, request access.

Request full access to PitchBook

Seattle Genetics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Seattle Genetics‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Seattle Genetics Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 09-Mar-2018 000000000000000000 00000 Biotechnology 0000 0000000 00.0
00000 00000 000000 01-Aug-2017 000000000000000000 000.00 Laboratory Services (Healthcare) 000000 00000 00.0
UNUM Therapeutics 11-Jun-2015 Early Stage VC 0000 Biotechnology 0000 0000000 00.0
To view this company’s complete investment and acquisition history, request access »

Seattle Genetics Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000 000000000000 11-Jun-2015 00000 00000 00 0000 Completed
  • 12 buyers
To view this company’s complete exits history, request access »

Seattle Genetics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Seattle Genetics‘s full profile, request access.

Request full access to PitchBook

Seattle Genetics Executive Team (14)

Name Title Board
Seat
Contact
Info
Clay Siegall Ph.D Co-Founder, President, Chief Executive Officer and Chairman
Todd Simpson Chief Financial Officer
Marc Lippman MD Director
Vaughn Himes Ph.D Chief Technical Officer
Matt Onsum Ph.D Executive

3 Former Executives

You’re viewing 5 of 14 executives. Get the full list »

Seattle Genetics Board Members (3)

Name Representing Role Since Contact
Info
Felix Baker Ph.D Baker Bros. Advisors Board Member 000 0000

2 Former Board Members

You’re viewing 1 of 3 board members. Get the full list »